创伤后头痛患者对降钙素基因相关肽超敏
这项随机双盲安慰剂对照交叉试验纳入30例轻度创伤性脑损伤后持续创伤后头痛至少12个月的患者,比较静脉输注CGRP与安慰剂后头痛加重情况。结果显示CGRP组70%出现伴偏头痛样特征的头痛加重,安慰剂组为20%(p<0.001),CGRP组头痛强度曲线下面积也显著更大,提示患者对CGRP超敏。
要点
- 持续创伤后头痛患者对CGRP超敏,支持其在病理生理中的作用。
- CGRP靶向治疗可能成为持续创伤后头痛的机制性治疗选择。
- 研究为随机双盲安慰剂对照交叉设计,分析采用意向性治疗。
核心结论
- 持续创伤后头痛患者对CGRP超敏,提示CGRP在病理生理中具有重要性。
- CGRP靶向治疗可能为持续创伤后头痛提供新的机制性治疗选择。
研究设计与样本
- 随机、双盲、安慰剂对照、两向交叉研究,采用意向性治疗分析。
- 纳入18至65岁、轻度创伤性脑损伤后持续创伤后头痛至少12个月的患者。
- 患者随机接受静脉输注1.5μg/min CGRP或安慰剂(等渗盐水)20分钟,在两个独立实验日进行。
- 共30例患者完成研究,平均年龄37岁,女性25例(83%)。
主要发现
- 12小时观察期内,CGRP组30例中21例(70%)出现伴偏头痛样特征的头痛加重,安慰剂组为6例(20%)(p<0.001)。
- 基线校正后的头痛强度评分曲线下面积在CGRP后显著大于安慰剂(p<0.001)。
临床怎么用
- 对持续创伤后头痛患者,可关注CGRP靶向治疗作为潜在机制性治疗选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To demonstrate that calcitonin gene-related peptide (CGRP) induces headache exacerbation with migraine-like features in patients with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (TBI). METHODS: A randomized, double-blind, placebo-controlled, two-way crossover study was conducted. Analyses were intention-to-treat. Eligible patients were aged 18 to 65 years and had a history of persistent PTH after mild TBI for at least 12 months. Patients were randomized to receive an intravenous infusion of 1.5μg/min of CGRP or placebo (isotonic saline) over 20 minutes on two separate experimental days. A 12-hour observational period was used to evaluate the following outcomes: (1) difference in incidence of headache exacerbation with migraine-like features and (2) difference in area under the curve for headache intensity scores. RESULTS: Thirty patients (mean age = 37 years, 25 women [83%]) were randomized and completed the study. During the 12-hour observational period, 21 of 30 patients (70%) developed headache exacerbation with migraine-like features after CGRP, compared with 6 patients (20%) after placebo (p < 0.001). The baseline-corrected area under the curve for headache intensity scores was significantly larger after CGRP, compared with placebo (p < 0.001). INTERPRETATION: Patients with persistent PTH are hypersensitive to CGRP, which underscores its pathophysiological importance. Furthermore, CGRP-targeted therapies might provide a novel mechanism-based treatment option for patients with persistent PTH. ANN NEUROL 2020;88:1220-1228.
引用
- Ashina H, Iljazi A, Al-Khazali HM, et al. Hypersensitivity to Calcitonin Gene-Related Peptide in Post-Traumatic Headache. Ann Neurol. 2020. PMID: 32959458. doi:10.1002/ana.25915
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。